Lisa Roberts
Family · Big Flats, NYNPI 1750558086
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Abbott at 37.9% of the total. Reporting peaked in 2022 at $3,310 and has fallen 69.6% since, to $1,007 in 2025. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 142 payments — averaging $56.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Spinal Simplicity, LLC$2K
- SPR Therapeutics, Inc$676
- Collegium Pharmaceutical, Inc.$586
- Johnson & Johnson$253
- E.r. Squibb & Sons, L.L.C.$243
- plus $1K from 18 others
What the payments were for
- Travel & lodging$2,12526%
- Food & beverage$4,45055%
- Education$1,45318%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 35 | $3,040 |
| Spinal Simplicity, LLC | 9 | $1,734 |
| SPR Therapeutics, Inc | 17 | $676 |
| Collegium Pharmaceutical, Inc. | 38 | $586 |
| Johnson & Johnson | 2 | $253 |
| E.r. Squibb & Sons, L.L.C. | 3 | $243 |
| Gilead | 2 | $200 |
| Si-bone, Inc. | 3 | $153 |
| Biohaven Pharmaceuticals, Inc. | 3 | $147 |
| Eisai Inc. | 1 | $124 |
| Boston Scientific | 5 | $119 |
| Ipsen Biopharmaceuticals, Inc | 1 | $103 |
| Daiichi Sankyo Inc. | 2 | $102 |
| Nevro Corp. | 3 | $96 |
| Novocure Inc. | 1 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $61 |
| AstraZeneca | 1 | $55 |
| Incyte Corporation | 1 | $54 |
| Biodelivery Sciences International, Inc. | 3 | $48 |
| Medtronic | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Pfizer | 1 | $31 |
| Seagen Inc. | 1 | $28 |
| Foundation Fusion Solutions, LLC | 2 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$2,013
- HA MINUTEMAN G3-R$1,435
- SPRINT PNS System$297
- RYBREVANT$253
- LAMITRODE$161
- Proclaim IPG$137
- NURTEC ODT$125
- LENVIMA$124
- Trodelvy$119
- CARVYKTI$119
- ONIVYDE$103
How this compares
$8,028 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 31 | $21,815 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 333 | $13,059 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 421 | $12,701 |
| Fentanyl | 38 | $6,770 |
| LinzessLinaclotide | 12 | $6,438 |
| OxycontinOxycodone Hcl | 15 | $5,986 |
| Oxycodone Hcl | 122 | $3,266 |
| Gabapentin | 225 | $3,008 |
| Hydromorphone Hcl | 123 | $2,782 |
| Pregabalin | 91 | $2,549 |
| Cyclobenzaprine Hcl | 192 | $1,893 |
| Lidocaine | 19 | $1,459 |
| Celecoxib | 48 | $1,170 |
| Tizanidine Hcl | 98 | $1,127 |
| Duloxetine Hcl | 52 | $974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $586 | $21,81531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Big Flats
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
- Fara StrickerGlen Oaks$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.